Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 2/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | CDC7 | O00311 | 1/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 7/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 7/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 7/20 | 0.34 |
| ▸ | GSK3B | P49841 | 2/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | WNT1 | P04628 | 1/20 | 0.33 |
| ▸ | FASN | P49327 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | CLK2 | P49760 | 2/20 | 0.33 |
| ▸ | CLK3 | P49761 | 2/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8259055 | 0.83 | CDC7 (0.37) | CSNK1DCDC7GSK3BGSK3AWNT1 | |
| SCHEMBL8255894 | 0.82 | CSNK1D (0.64) | CSNK1DADORA2ACNR1CNR2CDC7 | |
| SCHEMBL5374956 | 0.73 | CSNK1D (0.54) | CSNK1DADORA2AGSK3BGSK3AWNT1 | |
| SCHEMBL5379832 | 0.72 | CSNK1D (0.58) | CSNK1DWNT1CLK2CLK3DYRK1A | |
| SCHEMBL8253032 | 0.72 | MAP2K4 (0.58) | CSNK1DADORA2AWNT1CLK2DYRK1A | |
| SCHEMBL5372791 | 0.71 | CSNK1D (0.54) | CSNK1DWNT1CLK2CLK3DYRK1A | |
| SCHEMBL5372615 | 0.71 | CSNK1D (0.54) | CSNK1DADORA2AWNT1 | |
| SCHEMBL2471366 | 0.68 | GSK3B (0.47) | CDC7GSK3BGSK3ADYRK1A | |
| SCHEMBL8254726 | 0.68 | CSNK1D (0.73) | CSNK1DWNT1DYRK1A | |
| SCHEMBL5387284 | 0.67 | CSNK1D (0.68) | CSNK1DADORA2ACNR1CNR2CDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | disclosed |
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | disclosed |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | SIGNAL PHARMACEUTICALS, LLC | 2007-03-15 | — | — | US | disclosed |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | SIGNAL PHARMACEUTICALS, LLC | 2007-03-15 | — | — | US | disclosed |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | disclosed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | MAPK1, MAP3K1, MAPKAPK2 | CSNK1D 349/4885ADORA2A 2524/4885CNR1 1069/4885 |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | BCL9, MCL1, INMT | CSNK1D 1173/4885ADORA2A 1854/4885CNR1 1788/4885 |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | GPR119, JAK3, IGF1R | CSNK1D 410/4885ADORA2A 2097/4885CNR1 1432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.